Christy Shaffer, PhD


With over 20 years of experience in the life science industry, Christy is a seasoned entrepreneur and biotech executive. Following her career as a clinical scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co., she joined Inspire Pharmaceuticals in 1995 as the first, full-time employee. She was responsible for raising over $300m for the company, including taking the company public in 2000. As President and CEO, Christy grew the company from 20 scientists to nearly 250 employees with revenues of over $100 million. Under her leadership, Inspire was named as “Best Place to Work for Scientists” by the Scientist magazine, and “Best Place to Work in North Carolina.” Christy retired from Inspire in March, 2010 and the company was acquired by Merck in 2011. In addition to Graybug, Christy is currently the Managing Director of Hatteras Discovery and serves on three other Hatteras portfolio company boards: Clearside Biomedical, G1 Therapeutics and Kinodyn. Christy is a receptor pharmacologist by training, earning her PhD in Pharmacology from the University of Tennessee Health Science Center in 1985. She received her post-doctoral training at The Chicago Medical School and the University of North Carolina at Chapel Hill.

Gerald D. Cagle, PhD

Jerry is an experienced pharmaceutical executive with managerial, technical and business experience spanning more than three decades. He served in key leadership roles at Alcon, the world’s largest eye care company. Starting as a senior scientist in microbiology, he held several positions of increasing responsibility at Alcon, including Vice President of Product Development and Vice President of Regulatory Affairs. During his last 13 years at Alcon, he was Senior Vice President and Chief Scientific Officer. While at Alcon, Jerry was a regular contributor to new drug applications (NDAs) and premarket approvals (PMAs), holds approximately 20 issued patents and has authored a number of publications in the field.

Jeffrey L. Cleland, PhD

Jeff has 25 years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $450 million in capital at stages from Series A through D and exit via IPO including over $300 million in capital raised as CEO.  As the founding CEO of Versartis (VSAR), he led one of top biotech IPOs of all time. He held executive management positions at BaroFold, Novacea and Targesome, and has managed directly all aspects of pharmaceutical development and late-stage research. While at Genentech, Jeff served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, and Omnitarg®. He holds a BS in Chemical Engineering from the University of California, Davis and a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Jeff has authored more than 100 articles and 4 books, and holds several issued patents.

Emmett Cunningham, Jr., MD, PhD, MPH

Dr. Cunningham, currently a Partner, joined Clarus in 2006 with more than 20 years of experience in the biomedical and biopharmaceutical sectors. Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc (NYSE: PFE), where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit, a well-attended symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery.

Dr. Cunningham is a member of the Board of Directors of Annexon Biosciences, Restoration Robotics, and SFJ Pharmaceuticals Group; is a Board observer on Avillion and Lumos Pharma; and is on the Scientific Advisory Board of Aerie Pharmaceuticals (NASDAQ: AERI).

Justin Hanes, PhD

Justin is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine, where he holds joint appointments as Professor of Biomedical Engineering, Chemical & Biomolecular Engineering, Environmental Health Sciences, Neurosurgery, and Oncology. His degrees are in Chemical Engineering from UCLA (BS) and MIT (PhD), and he completed a postdoctoral fellowship in Oncology and Neurosurgery at Johns Hopkins prior to beginning his faculty position in 1998. Justin directs the Center for Nanomedicine at the Wilmer Eye Institute, where he oversees a large group focused on developing methods to improve the effectiveness of drug therapies for a variety of diseases, including those that affect vision. He currently serves as the Principle Investigator on numerous grants from the NIH and other agencies. He is an inventor named on numerous patents, and a few companies have been launched based on these inventions. He also serves at the Chairperson of the Gene and Drug Delivery study section of the NIH, on the Scientific Advisory Board of the Controlled Release Society, and on the editorial board for several scientific journals focused in the areas of biomaterials and drug delivery.

Chau Q. Khuong

Chau Q. Khuong is a Private Equity Partner. He joined OrbiMed in 2003. Mr. Khuong has experience in start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He was a summer Associate in the New Ventures technology transfer group at Columbia University. Mr. Khuong holds a BS in molecular, cellular and developmental biology with a concentration in biotechnology and an MPH with a concentration in infectious disease, both from Yale University.

Cameron Wheeler, PhD

Cameron is a Principal at Deerfield. Cameron joined Deerfield in 2014 and focuses on therapeutics companies. Prior to joining Deerfield, Cameron was at Eleven Biotherapeutics for more than five years, where he was responsible for corporate development and commercial strategy. He was instrumental in the founding, building, and the eventual public offering of Eleven Biotherapeutics. Prior to Eleven, Cameron was at Third Rock Ventures, a Boston-based venture capital firm focused on launching and building life science companies. While at Third Rock, Cameron gained business development and operating experience as a member of the founding team of Constellation Pharmaceuticals. Cameron holds a PhD and SM in Biological Engineering and an SB in Mechanical Engineering from Massachusetts Institute of Technology.